Macquarie Group
NGNE icon

Macquarie Group’s Neurogene NGNE Stock Holding History

Macquarie Group’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-697
Closed -$35 – 2051
2024
Q1 		$35 Buy
+697
New +$23.3K ﹤0.01% 1663
2021
Q4 		– Sell
-598
Closed -$86K – 2632
2021
Q3 		$86K Buy
598
+572
+2,200% +$87.6K ﹤0.01% 2033
2021
Q2 		$5K Hold
26
– – ﹤0.01% 2529
2021
Q1 		$6K Sell
26
-12
-32% -$3.07K ﹤0.01% 2440
2020
Q4 		$11K Hold
38
– – ﹤0.01% 2296
2020
Q3 		$9K Hold
38
– – ﹤0.01% 2292
2020
Q2 		$13K Sell
38
-241
-86% -$62.8K ﹤0.01% 2255
2020
Q1 		$63K Buy
+279
New +$57.4K ﹤0.01% 1767
2018
Q1 		– Sell
-30
Closed -$7K – 2305
2017
Q4 		$7K Buy
+30
New +$7.03K ﹤0.01% 2333

Other funds holding NGNE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Macquarie Group's NGNE Position: Q2 2024 in Review

Macquarie Group sold out of Neurogene (NGNE) in Q2 2024, closing a stake of 697 shares — an estimated $35 sold.

Macquarie Group first reported a position in NGNE in Q4 2017 and held it in 9 quarters. The position peaked at $86K in Q3 2021. 66 funds tracked by Wall St. Rank hold NGNE as of Q2 2024.

  • Macquarie Group reported no remaining Neurogene position as of Q2 2024 after selling out during the quarter.
  • Macquarie Group sold 697 Neurogene shares in Q2 2024, an estimated $35.
  • Macquarie Group first reported a position in Neurogene in Q4 2017 and held it in 9 quarters.
  • Macquarie Group's Neurogene position peaked at $86K in Q3 2021.
  • 66 funds tracked by Wall St. Rank held Neurogene as of Q2 2024.

Based on Macquarie Group's 13F filing for Q2 2024, filed 9 Aug 2024.